Michael Banitt, MD
Ophthalmology · Arlington, WANPI 1417006883
Payments from drug & device makers
What this record shows
This record is dominated by other: $7,475 of the $8,791 with a category attached, or 85.0%. Glaukos Corporation accounts for 85.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $7,988 and has fallen 96.1% since, to $308 in 2025. Among ophthalmology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $172.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$7K
- Alcon$395
- Biotissue Holdings Inc.$196
- Dompe US, Inc.$152
- AbbVie$129
- Bausch & Lomb Americas Inc.$72
- plus $351 from 10 others
Across 24 payments — averaging $986.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$24K
What the payments were for
- Food & beverage$1,24114%
- Gifts$751%
- Other$7,47585%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 2 | $7,496 |
| Alcon | 13 | $395 |
| Biotissue Holdings Inc. | 3 | $196 |
| Dompe US, Inc. | 6 | $152 |
| AbbVie(2 entities) | 5 | $129 |
| Bausch & Lomb Americas Inc. | 4 | $72 |
| Sun Pharmaceutical Industries Inc. | 3 | $56 |
| Thea Pharma Inc. | 2 | $44 |
| Tarsus Pharmaceuticals, Inc. | 2 | $40 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Merz Pharmaceuticals, LLC | 1 | $36 |
| Carl Zeiss Meditec USA, Inc. | 1 | $36 |
| Novartis | 2 | $30 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $29 |
| Rxsight Inc | 2 | $27 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$100
How this compares
$8,791 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $331,310 |
| Prednisolone Acetate | 877 | $30,705 |
| Ketorolac Tromethamine | 368 | $16,657 |
| Ofloxacin | 531 | $6,592 |
| Diclofenac Sodium | 348 | $3,625 |
| Alphagan PBrimonidine Tartrate | 11 | $2,215 |
| Loteprednol Etabonate | 11 | $1,747 |
| ValacyclovirValacyclovir Hcl | 14 | $1,692 |
| Fluorometholone | 25 | $1,599 |
| Latanoprost | 109 | $990 |
| Brimonidine Tartrate | 21 | $608 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $497 |
| Timolol Maleate | 71 | $478 |
| Tobramycin | 78 | $417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $152 | $331,31012 claims |
| AbbVieAlphagan P | $129 | $2,21511 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $29 | $1,74711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 428 ophthalmology providers in Washington.
Other ophthalmology in Arlington
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Todd SchneidermanSilverdale$200K
- Jennifer ChaoSeattle$188K
- Mark KontosSpokane Valley$175K
- Audrey RostovBellevue$155K
- John SamplesOlympia$115K
- Barbara SmitSpokane$110K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.